Fagron

Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024

20 2 2025 01:00:00 提供 Nasdaq GlobeNewswire

Fagron solidifies its leadership position with the acquisition of Guinama in Spain

04 2 2025 01:00:00 提供 Nasdaq GlobeNewswire

Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil

07 1 2025 01:00:00 提供 Nasdaq GlobeNewswire

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

23 12 2024 01:00:00 提供 Nasdaq GlobeNewswire

Disclosure of notification received from FMR LLC

26 11 2024 12:59:27 提供 Nasdaq GlobeNewswire

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

10 10 2024 01:00:00 提供 Nasdaq GlobeNewswire

Disclosure of notification received from AOC Pharma S.à r.l.

08 10 2024 16:00:00 提供 Nasdaq GlobeNewswire

Fagron completes share buy-back program

13 9 2024 12:28:48 提供 Nasdaq GlobeNewswire

Fagron’s share buy-back program: Weekly update

06 9 2024 12:24:46 提供 Nasdaq GlobeNewswire

Fagron’s share buy-back program: Weekly update

30 8 2024 12:34:33 提供 Nasdaq GlobeNewswire

Fagron’s share buy-back program: Weekly update

23 8 2024 12:44:55 提供 Nasdaq GlobeNewswire

Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024

01 8 2024 01:00:00 提供 Nasdaq GlobeNewswire

Fagron shareholders approve all voting items at AGM and EGM

13 5 2024 13:00:00 提供 Nasdaq GlobeNewswire

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

12 4 2024 02:00:00 提供 Nasdaq GlobeNewswire

Record revenue of €209 million in first quarter reflecting 15% topline growth

11 4 2024 01:00:00 提供 Nasdaq GlobeNewswire

Disclosure notification from Mawer Investment Management Ltd.

19 3 2024 13:00:00 提供 Nasdaq GlobeNewswire

Fagron publishes annual report 2023

14 3 2024 13:30:00 提供 Nasdaq GlobeNewswire

Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

15 2 2024 01:00:00 提供 Nasdaq GlobeNewswire

Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold

08 1 2024 02:00:00 提供 Nasdaq GlobeNewswire

Disclosure of notification received from BNP Paribas Asset Management SA

11 12 2023 12:00:00 提供 Nasdaq GlobeNewswire